Treace Medical Concepts, Inc. (NASDAQ:TMCI – Get Rating) insider Daniel E. Owens sold 6,250 shares of the business’s stock in a transaction on Wednesday, March 15th. The stock was sold at an average price of $22.87, for a total transaction of $142,937.50. Following the transaction, the insider now directly owns 30,914 shares in the company, valued at $707,003.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Treace Medical Concepts Trading Down 2.2 %
Shares of NASDAQ:TMCI opened at $23.00 on Friday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 3.77 and a current ratio of 4.41. The company has a fifty day simple moving average of $23.29 and a 200 day simple moving average of $22.97. Treace Medical Concepts, Inc. has a 12-month low of $12.48 and a 12-month high of $26.50.
Treace Medical Concepts (NASDAQ:TMCI – Get Rating) last issued its quarterly earnings results on Tuesday, March 7th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.05. The business had revenue of $49.77 million during the quarter. Treace Medical Concepts had a negative net margin of 30.19% and a negative return on equity of 54.51%. Analysts expect that Treace Medical Concepts, Inc. will post -0.8 EPS for the current year.
Institutional Trading of Treace Medical Concepts
Wall Street Analysts Forecast Growth
Separately, Morgan Stanley boosted their target price on shares of Treace Medical Concepts from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 8th.
Treace Medical Concepts Company Profile
Treace Medical Concepts, Inc, an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement.
- Get a free copy of the StockNews.com research report on Treace Medical Concepts (TMCI)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Treace Medical Concepts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Treace Medical Concepts and related companies with MarketBeat.com's FREE daily email newsletter.